What are the specific usage, dosage and course of treatment of Milizumab?

Milikizumab (Mirikizumab) is a new, highly selective antagonist of the p19 subunit of interleukin-23 (IL-23). It is a targeted biological agent. Its mechanism of action is to block the inflammatory pathway mediated by IL-23, thereby inhibiting the inflammatory response and alleviating intestinal lesions. It is widely used to treat moderately to severely active ulcerative colitis (UC) and Crohn's disease (CD). This drug has been approved in the European and American markets and has gradually become a key treatment option in the field of inflammatory bowel disease (IBD).

1. In the treatment of ulcerative colitis (UC), militizumab adopts a staged treatment strategy.

The induction treatment phase is mainly to quickly control symptoms and relieve inflammatory reactions. The recommended induction dose is 300mg, once per intravenous infusion, at the 0th, 4th and 8th weeks of treatment. Each infusion needs to be completed within at least 30 minutes to ensure that the drug enters the body slowly and evenly, thereby reducing the risk of adverse reactions. This stage is a critical period to evaluate the initial effect of the drug, and patients need to strictly follow the dosing schedule.

The goal of the maintenance treatment phase is to maintain remission for a long time and prevent recurrence. Starting from the 12th week, 200 mg each time is administered by subcutaneous injection. It is recommended to divide the injection into two injections (100 mg each time) and take it every 4 weeks. Subcutaneous injection has the advantages of easy operation and high patient compliance, and is suitable for long-term management and home use.

2. In the treatment of Crohn's disease (CD), considering the rapid progression of the disease and the more severe inflammatory erosion, the dose of militizumab is set relatively high.

The induction treatment period requires intravenous infusion of 900mg at 0, 4 and 8 weeks, with each infusion lasting at least 90 minutes. This helps to improve the initial concentration and therapeutic response of the drug in the body.

In the maintenance period, starting from the 12th week, a subcutaneous injection dose of 300mg is given every 4 weeks. The recommended practice is to divide it into continuous injections of 100mg and 200mg. The order of injections can be arranged arbitrarily. This dosing strategy reflects its flexibility and personalized treatment concept.

3. In terms of treatment schedule, the induction treatment cycle of militizumab is generally before12 weeks. If no obvious relief is seen during this period, the induction period can be extended to 16 weeks as appropriate. However, if the patient still does not respond after this period, a change of treatment strategy is usually recommended. After entering maintenance treatment, the drug can be used for a long time to maintain disease remission and quality of life, but the efficacy and safety of the drug need to be regularly evaluated.

4. In terms of medication precautions, before starting to use militizumab, tuberculosis screening, liver function testing and a comprehensive immune system assessment should be performed. During treatment, patients should avoid contact with active sources of infection, such as chickenpox, herpes zoster, etc. In addition, because Militizumab is a biological agent, it may cause injection-related adverse reactions during administration, such as fever, chills, or injection site redness and swelling. It is clinically recommended to have medical staff monitor you during infusion to ensure medication safety.

In general, the usage and dosage of militizumab should be formulated scientifically and individually, and the dosage should be accurately administered according to different disease types and treatment stages. Its strategy of intravenous induction and subcutaneous injection maintenance not only optimizes the treatment process, but also improves patient compliance and efficacy sustainability.

Reference materials:https://omvoh.lilly.com/